<DOC>
	<DOCNO>NCT01108055</DOCNO>
	<brief_summary>We combine oral investigational VEGF inhibitor call papopanib study kidney cancer combine standard chemotherapy call taxol patient relapse recurrent urothelial cancer .</brief_summary>
	<brief_title>Phase II Pazopanib Combination With Weekly Paclitaxel Refractory Urothelial Cancer</brief_title>
	<detailed_description>Based result Phase 1 study pazopanib combine paclitaxel activity paclitaxel urothelial cancer , test regimen disease unmet need appear appropriate .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologically confirm transitional cell carcinoma ( TCC ) urothelium ( bladder , renal pelvis , ureter , urethra ) . Mixed histology allow long predominant histology TCC 2 . First recurrence treatment maximum two chemotherapeutic regimen . 3 . Subjects must provide write informed consent prior performance studyspecific procedures assessment , must willing comply treatment follow . Procedures conduct part subject 's routine clinical management ( e.g. , blood count , image study ) obtain prior signing inform consent may utilize screen baseline purpose provide procedure conduct specify protocol . 4 . Age &gt; = 18 year 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 6 . Measurable disease criterion RECIST criterion 7 . Adequate organ system function define 1 . Absolute neutrophil count ( ANC ) &gt; = 1.5 X 10^9/L 2 . Hemoglobin &gt; = 9 g/dL 3 . Platelets &gt; = 100 X 10^9/L 4 . Prothrombin time ( PT ) international normalize ratio ( INR ) &lt; = 1.2 X upper limit normal ( ULN ) 5 . Total bilirubin &lt; = 1.5 X ULN 6 . AST ALT &lt; = 2.5 X ULN 7 . Serum creatinine &lt; = 1.8 mg/dL 8 . Urine Protein Creatinine Ratio ( UPC ) &lt; 1 8 . A female eligible enter participate study nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) . This include female : A hysterectomy A bilateral oophorectomy ( ovariectomy ) A bilateral tubal ligation Menopause Childbearing potential female must negative serum pregnancy test within 2 week prior first dose study treatment , preferably close first dose possible , agree use adequate contraception . Adequate acceptable contraceptive method , use consistently accordance product label instruction physician , follow : An intrauterine device document failure rate le 1 % per year . Vasectomized partner sterile prior female subject 's entry sole sexual partner female . Complete abstinence sexual intercourse 14 day exposure investigational product , dose period , least 21 day last dose investigational product . Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm spermicide ) . 1 . History malignancy within 5 year prior Day 1 except tumor negligible risk metastasis death , adequately control basal cell carcinoma , squamouscell carcinoma skin , carcinoma situ cervix , earlystage bladder cancer , lowgrade endometrial cancer Malignancies undergone putative surgical cure ( i.e. , localized prostate cancer postprostatectomy ) within 5 year prior Day 1 may discuss Medical Monitor 2 . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose study drug . 3 . Clinically significant gastrointestinal abnormality may increase risk GI bleed 4 . Clinically significant gastrointestinal abnormality may affect absorption investigational product 5 . Presence uncontrolled infection . 6 . Prolongation correct QT interval ( QTc ) &gt; 480 millisecond . On antiarrhythmic medication know prolong QT interval 7 . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) 8 . Poorly control hypertension [ define systolic blood pressure ( SBP ) &gt; =140 mmHg diastolic blood pressure ( DBP ) &gt; = 90mmHg ] . 9 . History cerebrovascular accident , hemoptysis , cerebral hemorrhage , clinically significant GI bleed , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month 10 . Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture 11 . Evidence active bleeding bleed diathesis . 12 . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance procedure . 13 . Patients strong CYP3A4 inhibitor 14 . Uncorrected abnormal electrolyte K , Mg Ca 15 . Prior treatment taxane chemotherapy 16 . Treatment follow anticancer therapy : radiation therapy , surgery tumor embolization within 14 day prior first dose pazopanib OR chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day five halflives drug ( whichever longer ) prior first dose pazopanib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>